|
Código del ensayo GO46021 |
|
Ensayo A phase ib/ii multicenter, open-label, randomized study evaluating the safety, pharmacokinetics, and activity of gdc-4198 alone and in combination with giredestrant in comparison with abemaciclib and giredestrant in participants with locally advanced or metastatic estrogen receptor-positive, her2-negative breast cancer who have previously progressed during or after a cdk4/6 inhibitor |
|
Estado Abierto a inclusión |
|
Localización Tumoral Mama |
|
Tipo de ensayo Ensayo de Fase II |
|
Tipo de tratamiento |
|
Situación clínica Metastásico |
|
Centro |
